What anti-inflammatory treatments are now recommended in HIV care?
Will this be the evolving standard of care for AID/CFS/autism?
From Perplexity
What anti-inflammatory treatments are now recommended in HIV care?
The primary anti-inflammatory treatment recommended in HIV care is the early and continuous use of antiretroviral therapy (ART), which substantially reduces systemic inflammation and immune activation—though not to the levels seen in HIV-negative individuals. Among ART regimens, integrase strand transfer inhibitors (INSTIs) like bictegravir and dolutegravir have shown particular benefits in lowering inflammatory markers compared to some older regimens.
In addition to ART, specific adjunctive anti-inflammatory therapies may be used in certain scenarios:
Statins are under research and sometimes used to address inflammation and reduce cardiovascular risk in HIV-positive patients.
Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and indomethacin can help relieve mild inflammation or symptoms related to HIV, but must be used cautiously due to potential renal and gastrointestinal effects, especially when combined with certain HIV medications.
Corticosteroids (e.g., prednisolone, dexamethasone) are used selectively, mainly for complications such as immune reconstitution inflammatory syndrome (IRIS), and their use is symptom-targeted and generally short-term.
Hydroxychloroquine and chloroquine have been investigated as immune-modulating drugs to reduce HIV-associated immune activation in select contexts, but are not widely adopted outside research settings.
Novel therapies such as obefazimod (ABX464) are being studied for anti-inflammatory effects and reduction of HIV reservoirs, and show promise for the future but are not yet standard of care.
Therapeutic approaches are tailored to individual needs and comorbidities, and ongoing research aims to identify safe and effective anti-inflammatory strategies to further improve outcomes for people living with HIV